Polatuzumab vedotin (new indication: diffuse large-cell B-cell lymphoma (DLBCL), in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP))

Subject:

• Active Substance: Polatuzumab vedotin
• Name: Polivy^®
• Therapeutic area: Diffuse large B-cell lymphoma
• Pharmaceutical company: Roche Pharma AG

Time table:

• Start: 01.06.2022
• Final decision by G-BA: 01.12.2022

Final decision:

• Hint for a non-quantifiable additional benefit